VTRS · Viatris Inc.
AI read · Good for VTRS
The AI's read
That points to greater confidence in Viatris shares from Barclays. The story gives no new sales, profit, or medicine results, so the positive read rests only on the firm's view.
Barclays raised its price target for Viatris to $25 from $22 and still thinks highly of the company.
Good for VTRS
Barclays raised its target and kept its Overweight rating, signaling a more positive view of Viatris shares. The report gives no new sales or profit results, so the support comes from analyst opinion alone.
Get alerts for VTRS
Follow Viatris Inc. (VTRS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VTRSFree on the App Store and Google Play, or on the web.